Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response.
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE.
Kleczko EK, et al. Among authors: selman am.
Cancer Lett. 2023 Mar 1;556:216062. doi: 10.1016/j.canlet.2023.216062. Epub 2023 Jan 16.
Cancer Lett. 2023.
PMID: 36657561
Free PMC article.